K Purzycka1, L M Peters2, J Elliott3, C R Lamb1, S L Priestnall2, A Hardas4, C A Johnston1, I Rodriguez-Piza5. 1. Queen Mother Hospital for Animals, Royal Veterinary College, University of London, North Mymms, UK. 2. Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, Hatfield, UK. 3. North Carolina State University, Department of Radiation Oncology, 1060 William Moore Drive, Raleigh, NC, 27606, USA. 4. Anderson Moores Veterinary Specialists, The Granary, Bunstead Barns, Winchester, UK. 5. Department of Oncology, Hospital Veterinari Glòries, Barcelona, Spain.
Abstract
OBJECTIVES: To summarise the clinical presentation and outcomes in a series of miniature schnauzers diagnosed with histiocytic sarcoma. MATERIALS AND METHODS: Retrospective review of medical records of miniature schnauzers diagnosed with histiocytic sarcoma between 2008 and 2019 at two referral centres in the UK. Signalment, clinical signs at initial presentation, imaging results and clinico- and histopathological findings, treatment type and outcome were recorded. Progression-free survival and overall survival time were calculated. RESULTS: Thirty dogs were included. Twenty-four of 29 dogs undergoing imaging of the thorax had lung and/or mediastinal involvement. The median overall survival time for dogs that were not euthanased within 3 days of diagnosis was 117 days (range 10 to 790). Three dogs underwent surgery; 13 received treatment with lomustine as a sole therapy - with partial responses documented on imaging in five of six dogs and 11 of 13 showing clinical improvement. CLINICAL SIGNIFICANCE: Histiocytic sarcoma should be considered as a differential diagnosis for miniature schnauzers with pulmonary masses. Although responses to treatment were common, they were usually short-lived because of the aggressive nature of the disease.
OBJECTIVES: To summarise the clinical presentation and outcomes in a series of miniature schnauzers diagnosed with histiocytic sarcoma. MATERIALS AND METHODS: Retrospective review of medical records of miniature schnauzers diagnosed with histiocytic sarcoma between 2008 and 2019 at two referral centres in the UK. Signalment, clinical signs at initial presentation, imaging results and clinico- and histopathological findings, treatment type and outcome were recorded. Progression-free survival and overall survival time were calculated. RESULTS: Thirty dogs were included. Twenty-four of 29 dogs undergoing imaging of the thorax had lung and/or mediastinal involvement. The median overall survival time for dogs that were not euthanased within 3 days of diagnosis was 117 days (range 10 to 790). Three dogs underwent surgery; 13 received treatment with lomustine as a sole therapy - with partial responses documented on imaging in five of six dogs and 11 of 13 showing clinical improvement. CLINICAL SIGNIFICANCE: Histiocytic sarcoma should be considered as a differential diagnosis for miniature schnauzers with pulmonary masses. Although responses to treatment were common, they were usually short-lived because of the aggressive nature of the disease.
Authors: Alysha M McGrath; Sarah A Salyer; Amanda Seelmann; Alycen P Lundberg; Melissa R Leonard; Joshua N Lorbach; Sarah Lumbrezer-Johnson; Eric T Hostnik; Giovanni Tremolada; Janis Lapsley; Laura E Selmic Journal: Front Vet Sci Date: 2022-02-09